MedTrace Logo

Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

NCT01492166 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1935

Last updated 2016-12-13

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.

Conditions

Interventions

DRUG

biphasic human insulin 30

Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492166 on ClinicalTrials.gov